secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001213900-24-049658
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment
-----------------------------------------------------------------------

- SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.
- Pre-clinical data showed effective, consistent exposure in a non-GLP small animal study completed Feb 2024.
- Silo expects to finalize an exclusive worldwide license with Columbia University in H1 2024.
- Next steps: PIND and GLP studies both slated to commence in H2 2024 before IND submission.
- Only two FDA-approved PTSD drugs exist; SPC-15 aims to increase stress resilience in high-risk populations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024049658/0001213900-24-049658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024049658/ea0207247-8k_silo.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-049658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer